Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28391001 | 0.97 | FDPS (0.38) | FDPSOPRM1SMPD1TSHRLMNA | |
| SCHEMBL641208 | 0.92 | FDPS (0.41) | FDPSOPRM1SMPD1TSHRTHRB | |
| SCHEMBL3073022 | 0.90 | SMPD1 (0.43) | FDPSOPRM1SMPD1TSHRTHRB | |
| SCHEMBL641726 | 0.90 | SMPD1 (0.43) | FDPSOPRM1SMPD1TSHRTHRB | |
| SCHEMBL4260580 | 0.90 | SMPD1 (0.43) | FDPSOPRM1SMPD1TSHRTHRB | |
| SCHEMBL14277926 | 0.85 | FDPS (0.34) | FDPSOPRM1 | |
| SCHEMBL640974 | 0.82 | FDPS (0.35) | FDPS | |
| SCHEMBL25272663 | 0.78 | FDPS (0.39) | FDPSOPRM1SMPD1TSHRLMNA | |
| SCHEMBL8367785 | 0.76 | FDPS (0.38) | FDPSOPRM1SMPD1TSHRLMNA | |
| SCHEMBL27863382 | 0.76 | NFKB1 (0.37) | FDPSTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12115161-B2 | Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient | KEIO UNIVERSITY (JP) | 2024-10-15 | — | — | US | disclosed |
| US-12077631-B2 | Bulk polymerisation of polyoxazolidone | BASF SE (DE) | 2024-09-03 | — | — | US | disclosed |
| CN-112424253-B | Bulk polymerization of polyoxazolidinones | 巴斯夫欧洲公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-112119063-B | Method for producing 3-difluoromethylpyrazole compound, method for producing 3-difluoromethylpyrazole-4-carboxylic acid compound, and pyrazolidine compound | 富士胶片株式会社 | 2023-10-17 | — | — | CN | disclosed |
| EP-3824012-B1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2022-09-07 | — | — | EP | disclosed |
| US-20210393634-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | KEIO UNIVERSITY (JP) | 2021-12-23 | — | — | US | disclosed |
| US-11180603-B2 | Polyoxazolidones and production thereof | BASF SE (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20210253782-A1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2021-08-19 | — | — | US | disclosed |
| EP-3824012-A1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3821893-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Keio University (JP) | 2021-05-19 | — | — | EP | disclosed |
| US-20080287684-A1 | Method for Producing Ionic Liquids | BASF SE (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287709-A1 | Method of Separating Acids from Chemical Reaction Mixtures by Means of Apolar Amines | BASF SE (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080190321-A1 | Cellulose Solutions in Ionic Liquids | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080164440-A1 | Solubility of Cellulose in Ionic Liquids With Addition of Amino Bases | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080083606-A1 | preparing aminodihalophosphines, diaminohalophosphines, triaminophosphines, phosphorous ester diamides, aminophosphines, diaminophosphines, phosphorous ester amide halides and aminophosphine halides with elimination of an acid in the presence of an auxiliary base | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | US | disclosed |
| US-7351339-B2 | Using an auxiliary base to form a salt with the acid which is liquid at low enough temperature so that value product does not decompose during the removal of the liquid salt; e.g. acid catalyst removal; ionic liquids | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20070269309-A1 | Method for Operating a Liquid Ring Compressor | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20070095645-A1 | Distillation of ionic liquids | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20050020857-A1 | Removal by salt formation | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| US-5472880-A | Adding a sterically hindered base to the solvent inducing the ionization of free amino acid, quantitatively measuring the conductivity | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287684-A1 | Method for Producing Ionic Liquids | HACL2, HAO2, SLC6A12 | FDPS 3994/4885OPRM1 3124/4885SMPD1 3796/4885 |
| US-20210393634-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TPMT, IL1B, TSLP | FDPS 250/4885OPRM1 4685/4885SMPD1 262/4885 |
| US-12115161-B2 | Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient | TPMT, IL1B, TSLP | FDPS 250/4885OPRM1 4685/4885SMPD1 262/4885 |
| US-20050020857-A1 | Removal by salt formation | PHOSPHO1, AASDHPPT, INPP5B | FDPS 1434/4885OPRM1 4835/4885SMPD1 297/4885 |
| US-20080287709-A1 | Method of Separating Acids from Chemical Reaction Mixtures by Means of Apolar Amines | APOB, ADAR, LIPA | FDPS 2042/4885OPRM1 1454/4885SMPD1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.